Specifically, in pancreatic cancer, isolation yield and anti-PDAC reactivity of TILs (CD4+, CD8+) can be improved by adjuvant use of immune checkpoint blockade (PD-1). This evidence concerns the gene PDCD1 and familial pancreatic carcinoma.